Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Sponsor: The First People's Hospital of Changzhou
Summary
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Official title: A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2015-07
Completion Date
2040-07
Last Updated
2015-07-15
Healthy Volunteers
No
Conditions
Interventions
Cytokine-induced killer cells (CIK)
Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.